Aytu BioScience Announces Appointment of David Green as Chief Financial Officer Englewood, CO

Aytu BioScience Announces Appointment

of David Green as Chief Financial Officer

Englewood, CO - December 18, 2017 - Aytu

BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the

field of urology, today announced the appointment of David A. Green as Chief Financial Officer. Mr. Green is a highly accomplished

CFO, who brings an extensive array of financial, accounting, and operational experience to Aytu, including a background at both

public and private life sciences companies over his twenty-five-year career. Effective today Mr. Green joins Aytu BioScience to

oversee the Company's finance and accounting functions, and will report directly to the Chief Executive Officer.

Prior to joining Aytu BioScience, Mr. Green served as Chief

Accounting Officer at Intarcia Therapeutics, a biopharmaceutical company currently engaged in late stage clinical development.

Prior to that, he was Chief Financial Officer of Catheter Connections, a commercial-stage medical device company that was acquired

by Merit Medical. Preceding Catheter Connections, Mr. Green was CFO at Specialized Health Products International, a publicly traded

medical device company that was acquired by C.R. Bard. Prior to his time serving in senior financial leadership roles at commercial-stage

specialty life sciences companies, Mr. Green was a Managing Director at Duff & Phelps, a global investment banking and corporate

finance advisory firm for nearly a decade. Mr. Green was also a founding member of Ernst & Young's Palo Alto Center for

Strategic Transactions, where he advised the firm's clients on using strategic transactions to accelerate growth. Mr. Green

earned a Bachelor of Science from the State University of New York, a Master of Business Administration from the University of

Rochester, and is a Certified Public Accountant.

"Dave's deep experience in finance, accounting and

operations at high-growth, commercial-stage life sciences companies, along with his extensive transactional, valuation, and strategic

planning expertise make him an excellent addition to Aytu's senior leadership team at this important stage of the Company's

growth," said Josh Disbrow, Chief Executive Officer of Aytu BioScience. "Dave's extensive background as a public

company CFO, paired with his experience across numerous transactions during his investment banking career, will be valuable to

Aytu as we continue to grow by increasing sales of our current portfolio of products, as well as through additional strategic transactions.

I welcome Dave and look forward to his contributions as a key member of our leadership team."

"I am excited to be joining Josh and his talented leadership

team at Aytu, and believe the Company is well positioned for tremendous value creation as we continue toward our objective of building

a leading specialty life sciences company with substantial prospects for growth," commented David Green.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty life sciences

company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality,

sexual wellness, and reproductive health. The company currently markets two prescription products in the U.S.: Natesto , the

first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T")

and ProstaScint (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA)

for prostate cancer detection and staging. Additionally, Aytu is developing MiOXSYS , a novel, rapid semen analysis system

with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress.

MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared, and Australian TGA approved

product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k medical device clearance by the FDA. Aytu's strategy

is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build

leading brands within growing markets. For more information visit aytubio.com. Aytu's wholly-owned subsidiary Aytu Women's

Health (formerly Nuelle, Inc.), is a personal health and wellness company focused on women's sexual wellbeing and intimacy.

Aytu Women's Health markets Fiera, a personal care device for women that is scientifically proven to enhance physical arousal

and sexual desire. Fiera is a consumer device and is not intended to treat, mitigate, or cure any disease or medical condition.

For more information about the Fiera personal care device visit fiera.com.

Forward Looking Statement

This press release includes forward-looking statements within

the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or

the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements

regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives

of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future

tense and/or are preceded by words such as "may," "will," "should," "forecast," "could,"

"expect," "suggest," "believe," "estimate," "continue," "anticipate,"

"intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable

terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events

or results to differ materially. These risks and uncertainties include, among others: risks relating to gaining market acceptance

of our products, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion

dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future

clinical trials, anticipated future regulatory submissions and events, and future events under our current and potential future

collaborations. We also refer you to the risks described in "Risk Factors" in Part I, Item 1A of Aytu BioScience, Inc.'s

Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time

Amato and Partners, LLC

Investor Relations Counsel